{
    "id": 19792,
    "fullName": "FASN positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FASN positive indicates the presence of the FASN gene,mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2194,
        "geneSymbol": "FASN",
        "terms": [
            "FASN",
            "FAS",
            "OA-519",
            "SDR27X1"
        ]
    },
    "variant": "positive",
    "createDate": "03/15/2016",
    "updateDate": "02/03/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8809,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, C75 inhibited growth of triple-receptor negative breast cancer cell lines in culture, regardless of their sensitivity to Adriamycin (doxorubicin) (PMID: 27106068).",
            "molecularProfile": {
                "id": 20205,
                "profileName": "FASN positive"
            },
            "therapy": {
                "id": 4818,
                "therapyName": "C75",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6760,
                    "pubMedId": 27106068,
                    "title": "Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27106068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8812,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGCG and Erbitux (cetuximab) synergistically inhibited growth of triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models, regardless of their sensitivity to Adriamycin (doxorubicin) (PMID: 27106068).",
            "molecularProfile": {
                "id": 20205,
                "profileName": "FASN positive"
            },
            "therapy": {
                "id": 4820,
                "therapyName": "Cetuximab + EGCG",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6760,
                    "pubMedId": 27106068,
                    "title": "Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27106068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8811,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, C75 and Erbitux (cetuximab) synergistically inhibited growth of triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models, regardless of their sensitivity to Adriamycin (doxorubicin) (PMID: 27106068).",
            "molecularProfile": {
                "id": 20205,
                "profileName": "FASN positive"
            },
            "therapy": {
                "id": 4819,
                "therapyName": "C75 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6760,
                    "pubMedId": 27106068,
                    "title": "Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27106068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8808,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGCG inhibited growth of triple-receptor negative breast cancer cell lines in culture, regardless of their sensitivity to Adriamycin (doxorubicin) (PMID: 27106068).",
            "molecularProfile": {
                "id": 20205,
                "profileName": "FASN positive"
            },
            "therapy": {
                "id": 4817,
                "therapyName": "EGCG",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6760,
                    "pubMedId": 27106068,
                    "title": "Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27106068"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20205,
            "profileName": "FASN positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}